Connect with us

Markets and industry

Synbiotic acquires 50.1% of cannabis group in significant merger for Europe

Synbiotic SE has acquired 50.1 per cent of Daniel Kruse’s cannabis group in what it has described as the most significant merger for the European cannabis sector. 

Published

on

Synbiotic acquires 50.1% of cannabis group in significant merger for Europe

Synbiotic SE, the largest listed cannabis company in Europe, has made the acquisition of cannabis industry pioneer Daniel Kruse’s group of companies at a valuation of €11.2m (~£9.53m).

The 50.1 per cent acquisition of Kruse’s companies will see Synbiotic SE securing the subsequent acquisition of the remaining 49.9 per cent by option. With the acquisition of the companies, Hanf Farm, Hempro International, Hemp Factory and MH medical hemp, Synbiotic is raising its sales forecast for 2021 to €15m (~£12.76m).

Synbiotic has said that the addition of the companies will enrich its portfolio with vital infrastructures and profitable brands.

CEO of SynBiotic, Lars Müller, commented: “The co-operation with Daniel Kruse is a genuine accolade in the cannabis sector. SynBiotic SE will benefit massively from what amounts to over half a century of combined know-how gathered by industry pioneers Daniel Kruse and Rafael Dulon. 

“So far, the only comparable acquisitions have taken place in Canada. This makes this merger the most significant in the European cannabis sector. I am greatly honoured by the trust Daniel Kruse and Rafael Dulon have displayed in SynBiotic SE; this shows that we are on the right track with our vision.”

Read more: Psychedelic entrepreneur Christian Angermayer acquires SynBiotic shares

Kruse, president of the European Industrial Hemp Association (EIHA) and industry pioneer with more than 25 years of experience in the sector, commented:  “After 25 years in the hemp industry, it is a great pleasure and honour for me to have found the right partner for the coming decades with SynBiotic SE. Our decades of experience alongside the supply chain of our group of companies find an excellent complement in the enormous dynamics of SynBiotic SE.

“The appealing nature and charisma of Lars Müller and his team contribute, but it is above all their displaying the highest professionalism and efficiency that has won us over. This combination makes SynBiotic SE the next Unicorn candidate and an ideal partner for me. The European hemp and cannabis market is set to become one of the most exciting and successful industries in the coming years. The challenges yet to be mastered are well known, but the resulting opportunities are unlimited.”

Rafael Dulon, managing director of Hanf Farm, the largest organic hemp farm in Europe, and expert member of the International Institute for Cannabinoids (ICANNA), has also worked in the hemp industry for 25 years. He was awarded the Global Hemp Innovation Award at the World Hemp Congress in 2015 for the development of a hemp harvester.

Dulon stated: “The synergies created for Hanf Farm through its inclusion in the SynBiotic SE Group will lead to significantly faster growth. Within SynBiotic SE’s strong network of people and companies, we will be much better able to implement our ambitious goals in expanding our capacities and competencies as an original agricultural producer and primary processor of hemp.

“I am very pleased that Lars Müller fully supports my ideas for the development of sustainable, organic agriculture. Together, we will use the great potential of hemp in agriculture and market our healthy, climate-friendly products even more vigorously, and as well develop many new products. I look forward to using my many years of experience to help support Lars Müller’s vision.”

Synbiotic is listed on the Frankfurt and Düsseldorf stock exchanges and announced plans to begin listing on the Canadian NEO Exchange in Toronto in October. 

Markets and industry

Industrial hemp in Europe driving global market growth

A new report has projected the market to exceed $310m by 2027.

Published

on

A new report has attributed the growing hemp market in Europe as a driving factor of global growth.
Home » News » Markets and industry » Synbiotic acquires 50.1% of cannabis group in significant merger for Europe

A new report has attributed the growing hemp market in Europe as a driving factor of global growth.

A once under-utilised crop, hemp is now seeing strong growth thanks to the demand for alternative products. Food, drink and personal care products are driving the growth of the industrial hemp market.

A new report from Global Market Insights has highlighted government regulations and policies associated with the legalisation of cultivation, as well as escalating demand for hemp products as a main driver of the market.

 The market size was over USD$205m (~£151.09m) in 2020 and is projected in the report to reach $310m by the end of 2027.

Fibre and seeds

Hemp is utilised extensively in the pulp and paper industry as it is a considerably more sustainable crop than wood. This is due due to the fact its does not need bleaching produces more pulp per acre, offers enhanced paper strength, and utilises chemicals that are less toxic compared to wood paper. 

The report highlights that government regulations seeking to limit wood harvesting and the associated harmful consequences of wood pulp and paper production, are likely to foster product uptake. 

Read more: Italy plans hemp production increases: could the UK be next?

It speculates the segment will see robust growth to attain a valuation of more than $70.5m by 2027.

The hemp seeds segment is slated to surpass a valuation of around $74.5m by 2027 under food and beverages application, due to their wide use in supplements, such as protein powder and meal replacement bars and snacks. 

Europe

The report has attributed a proliferating industrial hemp market in Europe as well as mounting product application in automotive manufacturing as additional drivers of growth in the global market.

It notes that the Europe industrial hemp market is projected to progress at a CAGR of approximately 5.5 per cent over the forecast period to surpass a valuation of $80.5m.

Growing consumer awareness of the plant’s therapeutic effects has also boosted product demand in recent years, according to the report. 

To read the full report please visit: https://www.gminsights.com/roc/3306.

Continue Reading

Markets and industry

Canxchange launches new trading system for the cannabis market

Canxchange is introducing more transparency, liquidity and efficiency to the growing cannabis market through its new platform.

Published

on

Canxchange launches new trading system for the cannabis market

Canxchange, the leading physical hemp and CBD exchange, has launched a new electronic trading system for the cannabis market to simplify sourcing, buying and selling.

The new Canxchange trading system is the result of more than one year of product development and engineering work. 

The platform provides electronic trading, market surveillance tools, price discovery options, data and features to enhance daily business and transactions for Canxchange members.  

CEO and co-founder of Canxchange, Alex Arkentis, commented: “As we continue to improve and upgrade Canxchange, our main objective is to facilitate our members based on their feedback and market needs. 

Read more: Canxchange benchmark report reveals outlook of European hemp market

“We have spent the past two years listening closely to what our members are looking for and educating ourselves on what the industry lacks. 

“With the launch of our latest platform, now our  traders can focus on their strategic priorities, and rely on Canxchange to handle everything else.”

The platform has been designed based on market and member feedback, to simplify the process of sourcing, buying and selling. 

New platform features include: 

  • Simplified processes and more powerful user experience 
  • Production and distribution procurement contracts 
  • Market surveillance tools 
  • Data and pricing analysis 
  • Micropayments 

It will leverage the expertise and proven track record of Canxchange, a European leader in physical cannabis trading with a reputation for world-class technology, cutting-edge service solutions and trading reliability and efficiency. 

Read more: How the cannabis industry is overcoming a lack of trust

Canxchange has said that it plans to continue developing its operation and network of users globally, following the success seen by adopters of the platform across Europe.  The company aggregates farmers, producers and extractors and a wide range of industries under one roof; offering a wide network of vetted businesses to its members.

Continue Reading

Markets and industry

Oxford Cannabinoid Technologies sees positive progression

Oxford Cannabinoid Technologies Holdings has begun 2022 with a positive start and has announced a new date for the start of its Phase I trial.

Published

on

Oxford Cannabinoid Technologies provides positive update

Oxford Cannabinoid Technologies Holdings (OCTP) had a positive year in 2021 and has begun 2022 on the same foot. 

The company has reported financial results for the six-month period ending 30 November 2021 in line with expectation, during which approximately £920k of research and development costs were incurred. The costs were primarily on lead drug candidate OCT461201, which accounted for approximately £604k of the total.

OCTP and its subsidiary, Oxford Cannabinoid Technologies Ltd. (OCT) had total cash reserves of approximately £12m and no debt, having repaid a Government bounce-back loan of £50k in full. The group has noted that progress is being made on all four of its programmes.

CEO, John Lucas, commented: “We are pleased with the progress made on all four programmes during the Period. OCTP remains on time, on budget and in line with our expectations. 

“This was a busy period for the company following the successful listing in May. 

“During the first half, we made good strides across the board and, as such are excited by the potential as the year progresses and look forward to updating the market further in due course.”

2021 also saw the company enter into agreements with leading global cannabis company Canopy Growth Corporation, as well as with Aptuit (Verona) SRL, a subsidiary of Evotec SE (Evotec).

OCTP’s agreement with Canopy Growth Corporation gives the company an exclusive license to Canopy Growth’s cannabinoid library. This includes 335 derivatives and 14 patent families. Oxford Cannabinoids has now begun screening the drug-like compounds in multiple therapeutic areas, including pain, neurology, immune-inflammation and oncology. 

OCTP is working with Dalriada Drug Discovery to screen the compounds and Oxford Cannabinoid Technology’s (OCT) existing proprietary cannabinoid library. Dalriada previously designed, synthesised, and experimentally tested all of the compounds in the Canopy library and as such, OCT will be able to leverage Dalriada’s existing knowledge and experience as it continues its experimental research. 

The aim is to identify two drug candidates for pre-clinical development by the end of 2022.

A further agreement with Oxford Stemtech announced in November 2021, is supporting the research and development for all the company’s drug development programmes, with a particular focus on programmes three and four.  

Stemtech’s “pain-in-a-dish” model replicates human pain using stem cells from volunteers that are re-programmed into pain neurons. This agreement also marks an evolution of OCTP’s relationship with Oxford University Professor, Dr Zameel Cader.

OCT also entered into a £2.6m contract research agreement with Aptuit (Verona) SRL, a subsidiary of Evotec SE (Evotec) in July 2021. 

Read more: Further drug development agreement for Oxford Cannabinoid Technologies

The company has confirmed in its update that the planning phase has been completed and “wet-work”, manufacturing process development and crystallisation development have now been initiated. 

It has also confirmed that it is anticipated that Evotec will provide the OCT with a submission-ready regulatory document and an approved batch of drug product that is ready for Phase 1 clinical trials by Q1 2023. 

Originally set to commence in Q3 2022, the date for the trial has been moved to Q1 2023 due to technical issues requiring additional optimisation of the crystal development for scale-up manufacturing, which has been now successfully implemented.

The OCT board has stated this will not impact time to Phase II clinical trials, there is no material cash flow impact and the time to market is currently anticipated to remain the same.

The agreement with Voisin remains on track according to the update with a roadmap ti clinical development having been generated to support the ongoing pre-clinical package for programme one.

Voisin has also undertaken activities in preparation for the commencement of the Phase I clinical trials and is providing the  Group with regulatory support to address immediate priorities for filing and registration of Programme 2’s metered-dose inhaler in the UK and US market.

Continue Reading
Sign up for the Cannabis Wealth newsletter

Recent Posts